POZEN Announces Licensing Deal with a Division of Johnson & Johnson for Migraine Treatment

POZEN Inc. POZN today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson JNJ, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru. MT 400 is POZEN's proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. POZEN previously licensed U.S.-only rights to MT 400 to GlaxoSmithKline GSK, who markets a different dose of MT 400 as Treximet.